title: [Streptococcus pneumoniae 19A-induced hemolytic-uremic syndrome: a new pathology?].
authors.forename: E
authors.initials: E
authors.lastname: Mérieau
authors.forename: P
authors.initials: P
authors.lastname: Lanotte
authors.forename: J
authors.initials: J
authors.lastname: Chantreuil
authors.forename: S
authors.initials: S
authors.lastname: Cantagrel
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001803:Blood Transfusion; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use; D002555:Cerebrospinal Fluid / Q000382:microbiology; D004359:Drug Therapy, Combination; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology*; D006801:Humans; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D011008:Pneumococcal Infections / Q000134:cerebrospinal fluid / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D013296:Streptococcus pneumoniae / Q000302:isolation & purification; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D002439:Cefotaxime